Psychopharmacologic validation of atypical depression

M. R. Liebowitz, F. M. Quitkin, J. W. Stewart, P. J. McGrath, W. Harrison, J. G. Rabkin, E. Tricamo, J. S. Markowitz, D. F. Klein

Research output: Contribution to journalArticlepeer-review

28 Citations (Scopus)

Abstract

Sixty patients meeting specific criteria for atypical depression completed 6 weeks of double-blind, randomly assigned treatment with phenelzine, imipramine, or placebo. Patients who had a history of spontaneous panic attacks or hysteroid dysphoric features showed extremely low placebo-response rates, moderate responses to imipramine, and high rates of response to phenelzine. Conversely, patients without such features responded moderately well to all three treatments. Based on preliminary data, MAOI-specific atypical depression does appear to exist, although in more delimited forms than previously recognized.

Original languageEnglish
Pages (from-to)22-25
Number of pages4
JournalJournal of Clinical Psychiatry
Volume45
Issue number7 II
Publication statusPublished - 1984

Funding

FundersFunder number
National Institute of Mental HealthP50MH030906

    ASJC Scopus Subject Areas

    • Psychiatry and Mental health

    Fingerprint

    Dive into the research topics of 'Psychopharmacologic validation of atypical depression'. Together they form a unique fingerprint.

    Cite this